Shire succumbs to £31bn takeover offer from US rival AbbVie
The deal as it stands, £24.44 in cash and 0.896 Abbvie shares, would give Shire’s investors a 25% stake in the combined company
Monday 14 July 2014
London-listed drugmaker Shire, best known for its Vyvanse treatment for attention deficit hyperactivity disorder, has been courted by AbbVie since early May when it tabled its first bid proposal.
The two boards are now locked in “detailed discussions” in New York following the improved £53.20-a-share proposal, but AbbVie looks to have succeeded where US rival Pfizer failed in its much bigger £63 billion bid for AstraZeneca.
The deal as it stands, £24.44 in cash and 0.896 Abbvie shares, would give Shire’s investors a 25% stake in the combined company. The shares rose 128.5p to 4998.5p.
“The board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the revised proposal to Shire shareholders. Accordingly, the board is in detailed discussions with AbbVie in relation to these terms,” said the company.
The pursuit of Shire has stoked far less controversy than AstraZeneca because, apart from offices in Basingstoke, it is headquartered in Dublin but managed from Boston. The vast majority of Shire’s staff and sales are in the US.
AbbVie covets Shire’s rare diseases unit, bolstered by the $4.2 billion deal for US company ViroPharma last year, which the company is building up in response to more generic competitors to its ADHD drugs. It also wants Shire’s portfolio to reduce its reliance on top-selling rheumatoid arthritis drug Humira, which accounts for 60% of its sales but loses US patent protection in late 2016.
AbbVie, led by Richard Gonzalez, is looking to cut its US tax bill by moving its tax base to Britain, in a tactic known as inversion.
Mick Cooper, analyst at Edison Investment Research, said: “It is pleasing to see the two boards working well together and the proposed offer seems a fair price that represents good value for both companies’ shareholders.”
Shire previously fought to maintain its independence as chairman Susan Kilsby unveiled a new target to double annual product sales, which account for the bulk of revenues, to $10 billion by 2020.
The company was founded in 1986, with early successes including a range of calcium products to treat osteoporosis, and listed in 1996.
Comment: Behaving like grown-ups
IF Pfizer’s Ian Read was ever tempted to have another tilt at AstraZeneca he could do worse than look at how Shire and AbbVie have conducted themselves over the past few weeks.
Shire is a US firm in all but tax-base and listing, and so hasn’t inspired the same political sound and fury that Astra did, but what also stands out is the grown-up way in which the two boards have gone about their business. Pfizer’s sally was marked by its aggressive public tubthumping and precious little effort to engage the board. AbbVie and its target kept the exchanges cordial but forthright, the big shareholders had their say and Shire was willing to sit down when the US firm’s offer came into the ballpark.
The result is nearly $14 a share extra for Shire’s shareholders and an offer at a 53% premium to the price before the first approach. All with a minimum of fuss. Chair Susan Kilsby has done a good job: she might even get a few offers herself.
- 1 Malaysian cyclist could face disciplinary action after 'Save Gaza' gloves protest
- 2 Is Gideon Levy the most hated man in Israel or just the most heroic?
- 3 Fifty Shades of Grey trailer provokes moral outrage from US parenting groups
- 4 McDonald’s removes chicken nuggets from the menu in Hong Kong amid major food scare
- 5 Students offered grants if they tweet pro-Israeli propaganda
The 'scroungers’ fight back: The welfare claimants battling to alter stereotypes
Arizona execution lasts two hours as killer Joseph Wood left 'snorting and gasping' for air
Malaysia Airlines MH17 crash: Ukrainian military jet was flying close to passenger plane before it was shot down, says Russian officer
Malaysia Airlines MH17 crash: Massive rise in sale of British arms to Russia
Malaysia Airlines MH17 crash: victims’ bodies bundled in black bags and loaded onto trains
John Barrowman praised for Commonwealth Games opening ceremony gay kiss
iJobs Money & Business
£600 - £650 per day: Orgtel: Conduct Risk Liaison Manager - Banking - London -...
£18000 - £23000 per annum + Comission: SThree: SThree, International Recruitme...
£280 - £300 per day + competitive: Orgtel: Test Analyst, Edinburgh, Credit Ris...
£20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...